Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Advance Auto Parts, Inc. (AAP) vs Moderna, Inc. (MRNA) Price & Performance

Advance Auto Parts, Inc.
Moderna, Inc.

Price performance

Price movement over the last 24 hours

Key statistics

Advance Auto Parts, Inc. vs Moderna, Inc. — how do they compare? Advance Auto Parts, Inc. trades at $54.94 (market cap $3.37B), while Moderna, Inc. trades at $74.17 (market cap $31.65B). The key difference: Moderna, Inc. is far larger — about 9.4× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays a 1.79% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

AAPMRNA
Market Cap
$3.37B$31.65B
Sector
Consumer CyclicalHealth
52-Week High
$66.50$81.80
52-Week Low
$38.75$22.36
Enterprise Value
$5.64B$27.74B
Dividend Yield
1.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Advance Auto Parts, Inc.

Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.

The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.

Moderna, Inc.

Moderna (MRNA) trades at $79.77, up 0.01% on the day, with a bullish technical signal from moving averages and positive momentum from recent pipeline news. The stock has seen significant gains, driven by FDA progress on its mRNA flu vaccine and expansion into oncology and rare diseases. However, fundamentals show persistent losses, with a net income margin of -144.92% in 2025 and declining revenue from pandemic peaks, though quarterly EPS has beaten expectations recently.

The outlook is mixed: strong technical momentum and pipeline diversification offer upside, but high valuation ratios and sustained unprofitability pose risks. Analyst consensus is cautious with a $48.83 price target, suggesting 39% downside, indicating Wall Street sees limited near-term fundamental support despite recent bullish sentiment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Advance Auto Parts, Inc.

Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.

Read more on AAP

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA